Deep Science Publishing, 2025
https://doi.org/10.70593/978-93-7185-087-2_7

Chapter 7: Translational Challenges and Future Directions in 3-D for PCOS Nanotherapy

Sami Ahmad[1], Kamal Kumar Daal[1], Divyansh Bhatnagar[2], Rishabh Gupta[1], Km. Shweta Singh[3], Vandna Tiwari[4], Subhanshi Vishwas[5], Shivang Shukla[1]*

[1]Department of Pharmacy, Jagannath University Chaksu Campus, Jaipur- 303901, Rajasthan, India
[2]School of Pharmacy, Suresh Gyan Vihar University, Gyan Vihar Marg, Jagatpura, Jaipur- 302017, Rajasthan, India
[3]Amity Institute of Pharmacy, Amity University, Lucknow-226010, Uttar Pradesh, India
[4]Medical Officer in Navyog Kendra Tanakpur, Uttarakhand, India
[5]Applied Science, Department of Chemistry, Invertis University, UP, India.

Corresponding Author*
Mr. Shivang Shukla (PhD, M Pharm)*
Email: *Shivang.shukla20@gmail.com*

Abstract

Polycystic Ovary Syndrome (PCOS) is a multifactorial endocrine and metabolic disorder with complex pathophysiology characterized by dysregulations of various hormones, insulin resistance, and chronic inflammation, and continues to pose difficulties to standard treatment. The advent of nanotechnology is likely to provide effective and bioaccessible treatment due to its capabilities in targeted and sustained drug release. Recently, 3-Dimension (3-D) nanotherapeutic model cell cultures, organoids, and bioprinted ovarian tissues have transformed PCOS preclinical investigations as these provide clinically accurate simulations for drug and mechanism of action screening, albeit there are still several hurdles to overcome for these models to clinically serve PCOS patients, including reproducibility and scalability, regulatory difficulties, and minimal clinical validations. This chapter discusses the challenges related to the translation of 3-D nanotherapy, PCOS, and the ethics and regulations of the technology. In addition, artificial intelligence, omics, and microfluidic organ-on-chip systems are discussed to further preclinical and clinical integration. This chapter aims to provide a roadmap for the integration of nanomedicine, bioengineering, and reproductive endocrinology to advance personalized and precision nanotherapy for PCOS.

Keywords: *Polycystic Ovary Syndrome (PCOS); Nanotherapy; 3-Dimensional Models; Organoids; Translational Medicine; Drug Delivery; Bioengineering; Future Prospects; Reproductive Nanomedicine*

1. INTRODUCTION

A large number of women in their reproductive years are affected by Polycystic Ovarian Syndrome (PCOS), which is a complex end metabolic issue that reports of between 6 and 20% depending on the study and what they are looking at. Also in current research shows that although PCOS was first identified as a reproductive issue, which includes polycystic ovarian morphology, hyperandrogenism and chronic anovulation, it is in fact a systemic issue that has far-reaching therapeutic issues. Also, at the time of its identification, PCOS was thought to be a reproductive issue, but now it also plays a role in obesity, dyslipidemia, insulin resistance and also presents a higher risk of cardiovascular disease and type 2 diabetes. In addition to the metabolic issues, it also has a large role in mental health issues, which include anxiety, depression and a lower quality of life. Women who have PCOS present a great deal of varied symptoms which range from irregular menstrual cycles to infertility, acne and hirsutism. This clinical diversity in presentation makes diagnosis and treatment a challenge. There is a great deal that is put down to lifestyle, environmental, and hereditary factors, which in turn point to the syndrome's complex nature and the need for treatments that will address the metabolic, psychological, and reproductive aspects at the same time. (Friederich & Lazarova-Molnar, 2024)

The present set of PCOS treatments is geared toward symptom management, which in turn does not address the complex physiopathology of the issue. The primary line of treatment is that of lifestyle, which includes diet control and weight management. Pharmacological options are insulin sensitisers like metformin, which are used for metabolic issues, anti-androgens for cosmetic issues and also oral contraceptives, which are used to regulate the period and to manage hyperandrogenism. Women who are infertile and do not respond to conventional ovulation induction often turn to assisted reproductive technology. (Friederich & Lazarova-Molnar, 2024). These methods present a great deal of trade-off, which at the same time are very useful. Insulin sensitizers report variable results between groups, hormonal therapies may, in fact, increase metabolic risk factors, and many women see only partial or no benefit from what is put forward. Also, it is found that present protocols, which do not include the metabolic, psychosocial, and reproductive elements of the disorder which in turn lead to poor disease management. These deficiencies stress to develop new and comprehensive treatment approaches that are improved in terms of safety, targeting ability and long-term results. (Recent Advances in the Management of Polycystic Ovary Syndrome: A Review Article - PMC, n.d.).

In recent years, nanomedicine has seen great promise in terms of its role in PCOS treatment. Among the put forth by nanotechnology is improved bioavailability of poor drugs, controlled release of the drug, target delivery to the ovary or metabolic sites, and also ability to reduce systemic toxicity. In preclinical settings, it has been shown that nanoencapsulation of phytoconstituents, insulin sensitisers, and antioxidants which in turn improves treatment results. Also, the nanocarriers present a combination therapy

which in turn addresses the inflammatory, metabolic, and endocrine aspects of PCOS at the same time. Also, in addition to these, 3D technologies like organoids, spheroids and organ-on-a-chip are transforming *in vitro* PCOS research. 3-D systems closely mimic the ovarian milieu than traditional two-dimensional cultures, providing information on follicular development, hormone interactions, and medication responsiveness in physiologically realistic settings(Rafiya et al., 2025). By way of providing reliable models for drug screening, toxicity evaluation, and development of individualised treatment plans which is what these platforms that improve translational research. There is a very synergistic play between 3D tech and nanomedicine, which has the potential to transform PCOS research and treatment. But it is also true that are a need to overcome many issues in taking these findings from the bench to the bedside. Therapeutic optimization is complicated by bio-based issues like immune clearance of nanoparticles, patient response variation, and the very complex hormonal picture in PCOS. Also, still large gaps between preclinical and clinical research, as although animal models may present certain results, they do not always translate to human populations. Clinical acceptance is further limited by manufacturing challenges, such as problems with cost-effectiveness, repeatability, stability, and scalability(Liang et al., 2023). In many cases of nanomedicine applications, regulatory issues and the issue of long-term safety have equal importance, which is not sufficient. This paper aims to put into focus that in order for us to see the full play of nanotech and modern biotech in PCOS treatment, we do have to research and come up with solutions to these issues. Hence, this review aims to present a critical analysis of the role that 3D tech and nanomedicine are playing in PCOS and also to bring to the fore the translational issues that cause their clinical implementation to be a challenge. The aim in the discussion is to put out there the main issues at hand and the opportunities in this area, which in turn will, in the end, design the next generation of treatments that we can present to not only improve clinical outcomes but also to put in place cost-effective, total, and long-term solutions for women with PCOS. (Muthukumaran & Shanmugam, 2024a).

2. THE PROMISE OF NANOTHERAPY IN PCOS

2.1 Mechanistic insights: hormonal imbalance, oxidative stress, metabolic dysfunction

PCOS is a hormonal disorder characterized by the triad of anovulation, excessive male hormones, and the presence of multiple cysts in ovaries. In terms of mechanism, the hypothalamic-pituitary-ovarian axis becomes imbalanced in a way that stimulates the secretion of luteinizing hormone (LH) and reduces that of follicle-stimulating hormone (FSH) resulting in the production of androgens and lack of follicular development. Besides the hormonal imbalance, oxidative stress is also relevant to the development of PCOS. The excess production of reactive oxygen species (ROS), the reduced ovarian antioxidant and the antioxidant defense mechanisms, and the chronic systemic low-grade inflammation work together to cause ovarian dysfunction, insulin resistance, and inflammation(Chen & Pang, 2021). This oxidative environment also promotes greater

endothelial dysfunction and higher cardiometabolic risk. In PCOS, metabolic disorders like poor glycemic control, dyslipidemia, and central obesity are very frequently seen that link the condition to type 2 diabetes and cardiovascular disease. The interplay of hormonal imbalance, oxidative stress, and metabolic dysfunction in what I would call a cycle that is the root cause of disease progression and which also does not respond well to current treatments, thus pointing out the need for introducing new treatment methods such as nanotechnology. ("Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases," 2024).

2.2 Nanoparticle-based strategies

Nanoparticle-based drug delivery systems offer unique opportunities to overcome the therapeutic limitations in PCOS management. Liposomes, spherical vesicles composed of phospholipid bilayers, are versatile carriers capable of encapsulating both hydrophilic and hydrophobic drugs. They enhance the bioavailability of poorly soluble molecules, allow targeted ovarian delivery, and minimize systemic toxicity("Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases," 2024). Polymer-based nanoparticles of PLGA or chitosan which are used for drug delivery, provide for controlled and sustained release, protection of therapeutics from breakdown, and also that they may be modified with ligands which in turn enable very specific action in ovarian and endometrial tissues. As for metal-based nanoparticles which include gold and silver, they have antioxidant, anti-inflammatory, and insulin-sensitising actions. For example, gold nanoparticles have been forward they scavenge ROS, bring down androgen levels and at the same time modulate insulin signal transduction in preclinical PCOS models. (*Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review - PMC*, n.d.). Hybrid nanoparticles that bring together the structural benefits of polymers with the functional benefits of metals and lipids are at the forefront of what is to come in nanomedicine. These systems are able to load multiple drugs, to present combination therapy, and at the same time perform real-time imaging through a design that is therapeutic and diagnostic. Also, for instance, a hybrid lipopolymeric nanoparticle may present the action of metformin for improved insulin sensitivity and resveratrol as an antioxidant, and also in which metal cores that enable non-invasive imaging. As a whole, these nanotech-based methods aim to restore hormone balance, reduce oxidative stress, and improve metabolic health in PCOS patients. (Rai et al., 2025).

2.3 Advantages over conventional therapy

Standard PCOS treatments such as oral contraceptives, anti-androgens, and insulin sensitisers are often limited by a lack of patient compliance, systemic adverse effects, and poor clinical effectiveness. Nanotechnology also has the potential to increase effectiveness, reduce adverse effects, improve compliance, and increase patient satisfaction. First, nanoparticles can improve targeting of therapies, increasing

therapeutic concentration at the ovaries and/or endometrium, and reducing toxicity at off-target tissues. Second, polymeric systems provide controlled drug release, having prolonged effects, requiring decreases in dosing frequency, and thus enhancing compliance. (Vasudevan et al., 2025). Third that they put into play the bioavailability of phytochemicals and small molecules, which have low solubility, like curcumin or resveratrol, which in large doses do not see great clinical success. Also, that nanoplatforms are a design basis for multi-functional action, which is into the same package anti-inflammatory and insulin-sensitising actions. By this, they in turn reduce systemic side effects and at the same time increase therapeutic index, which is that they do personalised, safe and very effective interventions for PCOS as compared to present treatment methods. (Serrano et al., 2023).

2.4 Preclinical evidence and proof-of-concept studies

In PCOS models, an increasing collection of preclinical data supports the efficacy of nanoparticle-based treatments. In mouse models, liposomal versions of clomiphene citrate and letrozole have shown better follicular response and ovulation rates than free medications. Polymeric nanoparticles containing metformin or thiazolidinediones revealed better insulin sensitivity, reduced oxidative stress indicators, and improved ovarian morphology in preclinical PCOS(Muthukumaran & Shanmugam, 2024b). Metallic nanoparticles, especially of gold and selenium reported to have reduced androgen levels, normalised oestrous cycles, and improved ovarian antioxidant capacity. From hybrid nanosystems that deliver herbs like curcumin or quercetin, it is seen that these products play a dual role of reducing system-wide inflammation and simultaneously restoring reproductive function. While most of this research is at the preclinical stage, proof-of-concept studies put forth a strong case that nanoparticle-based approaches do, in fact, address the many facets of PCOS. They are the beginning of what may see translation into early-phase clinical settings once standardized manufacturing practices are put in place, safety is proven out, and regulatory approval is gained. (*Advancements in Lead Therapeutic Phytochemicals Polycystic Ovary Syndrome: A Review - PMC*, n.d.).

3. 3D MODELS IN PCOS RESEARCH AND THERAPY

3.1 Evolution from 2-D to 3-D cell culture

Traditional 2D monolayer cultures have used for a long time to study PCOS-related cellular pathways, do indeed fall short in terms of what they replicate of the complex ovarian microenvironment. In 2D systems loss of cell polarity, three-dimensional interactions and matrix-dependent signaling which in turn produces simplified results that do not in fact predict *in vivo* behaviour. It is observed that a shift towards 3D cell culture, which comes into play to fix these issues. 3D models do a better job at recreating tissue-specific architecture, cell-to-cell and cell-to-matrix interactions which in turn gives us a more physiologically relevant model for the study of PCOS

pathophysiology. This shift has also enabled researchers to look at folliculogenesis, insulin signalling and inflammatory responses under disease-relevant conditions. (*Overcoming the Barriers of Two-Dimensional Cell Culture Systems with Three-Dimensional Cell Culture Systems: Techniques, Drug Discovery, and Biomedical Applications - ScienceDirect*, n.d.).

3.2 Organoids and spheroids for ovarian and endometrial studies

The development of organoids and spheroids has made it possible for reproductive biology to model ovarian and endometrial tissues like never before. Self-assembled ovarian granulosa or theca cell spheroids can replicate and mimic a follicular microenvironment to study hormonal and drug actions and oxidative stress. In the studies of PCOS, the ovarian spheroids have been shown to mimic the steroidogenesis and proliferation changes of these patients when exposed to hyperandrogenic or hyperinsulinemic conditions. Organoids are even more complex, made from primary tissues or stem cells. Ovarian organoids can be site-specifically modified to include heterogeneous cell populations, which allow for the detailed study of various processes such as ovulatory dysfunction, follicle maturation, and excess androgen. (*Human Organoid Systems in Modeling Reproductive Tissue Development, Function, and Disease | Human Reproduction | Oxford Academic*, n.dIn the case of endometrial organoids, modelling of implantation defects and menstrual irregularities, which are common in PCOS. As for spheroids and organoids, they present as platforms for high-throughput drug screening, toxicological testing and in the area of personal medicine which is made possible by the use of patient-derived models that in turn reflect individual variability. Also in nanotherapy research, they are very valuable as these models allow for the study of nanoparticle uptake, biodistribution and therapeutic results in a microenvironment that very much resembles *in vivo* tissue. (*Endometrial Organoids and Their Role in Modeling Human Infertility - PubMed*, n.d.).

3.3 3-D bioprinting for reproductive tissue engineering

3D bioprinting has been put forth as a game-changing tool in regenerative medicine and a great promise in its role in reproductive tissue engineering in PCOS. The bioprinters deposit bioinks that include ovarian and endometrial cells into biomaterial scaffolds, which in turn present the development of very organised tissue structures. This tech also brings about the precise spatial arrangement of many cell types, thus creating a follicular niche and vascularized ovarian stroma. In case of PCOS, the 3D bioprinted ovarian models can be used to study follicular arrest, stromal fibrosis, and hyperthecosis in a controlled setting. (Serrano et al., 2023). Furthermore, bioprinting opens avenues for creating implantable grafts for ovarian regeneration and, consequently, the possibility of offering fertility-restoring therapies to women with severe PCOS-related infertility. The combination of bioprinting and nanotechnology adds to the promise of this area of research since the nanoparticles that can be added to bioinks to deliver growth factors, hormones, or antioxidants in a spatial and temporal

controlled system can help transition from basic science to applied therapy. (Muskan et al., 2022).

3.4 Advantages of 3-D models in PCOS pathophysiology

3D models present many benefits over traditional methods of studying PCOS pathophysiology. There are, Unlike animal models, which are expensive and which also introduce the issue of interspecific variation, 3D culture systems allow for controlled and human-relevant research. Also, they preserve the structure and function of ovarian and endometrial tissues, which in turn allows for the study of follicular dynamics, insulin resistance and inflammatory responses. Also of great importance is that 3D systems which are created from patient tissue samples, allow for personal disease modelling, which in turn facilitates individualised drug testing and precision medicine. (Erten & Yılmaz, 2018). In the case of nanotherapy development, 3D cultures present an intermediate step between 2D *in vitro* studies and *in vivo* trials which in turn allows for the study of nanoparticle penetration, cellular uptake, and therapeutic response in a very real tissue-like setting. Also, by very accurately representing the complex ovarian microenvironment, 3D models put forth a platform that supports translation research and which may in fact be the key to bridge the gap between findings in the lab and what works in practice for PCOS(C. H. Park et al., 2024).

4. TRANSLATIONAL CHALLENGES IN NANOTHERAPY FOR PCOS

The use of nanotherapy in the treatment of PCOS has now reached a stage where the problems, which prevent its application, are almost the same as those faced during It is touted that there the benefits of nanomedicine such as targeted delivery, increased absorption, and reduced side effects, but still there are monumental barriers to proper clincial translation that need to be overcome (Nanoparticles for Polycystic Ovary Syndrome (PCOS) Therapy: Exosomes and Synthetic Nanoparticles, Challenges and Opportunities - PubMed, n.d.). The major barriers include the biological delivery problems, the complexities of dose optimization, and the lack of reproducibility across different models, as well as concerns about long-term safety and manufacturing challenges that affect both scalability and cost-effectiveness. Overcoming the above-mentioned difficulties will have a great impact on the development of safe and effective nanotherapy for patients with PCOS, which are also friendly (Muthukumaran & Shanmugam, 2024c).

4.1 Biological Barriers to Nanoparticle Delivery

PCOS is characterized by a variable set of clinical features that include hormonal imbalances, insulin resistance, ovarian cyst development, and metabolic issues which in turn comp which targeted nanocarrier delivery. Nanocarriers must circulate in the blood for a great length of time; also, they must get past the ovarian microenvironment which is noted for it's dense stromal tissue, cystic structures, and altered vasculature(*Recent Review on Biological Barriers and Host–Material Interfaces in*

Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies - PMC, n.d.). Also the reticuloendothelial system (RES) very quickly clears out nanocarriers which in turn reduces therapeutic results. Also with the issue of fluctuating hormones in PCOS that biodistribution and nanocarrier uptake also become very unpredictable which in turn plays a role in variable therapeutic results. (*Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery | Nature Biotechnology*, n.d.). Given how PCOS has both reproductive and metabolic clinical manifestations, nanocarriers will likely need to be delivered to tissues like the ovary, endometrium, and peripheral tissues like fat and liver. To circumvent these challenges, researchers are exploring PEG coating to increase circulation time, ligand-functionalized nanoparticles for targeted delivery to the ovaries, and a biomimetic coat for immune camouflage. Even with these technological advances, the heterogeneous nature of this group of PCOS patients presents the biggest translational obstacles.(*Principles of Nanoparticle Design for Overcoming Biological Barriers to Drug Delivery | Nature Biotechnology*, n.d.).

4.2 Dose Optimization and PK/PD Challenges

Determin out that which is the best dose of nanomedicine for PCOS is made difficult by the fact that nanparticles have unique PK and PD profiles. Unlike traditional drugs is the absorption, distribution, metabolism, and excretion of nanparticles are very much a function of size, surface charge, and form of the preparation. Also in very small changes in make-up may bring forth great changes in circulation time and tissue penetration. Also in into the fact that PCOS patients present with very variable physiologic states, which include obesity, insulin resistance and hormonal imbalance which in turn play a role in nanoparticle biodistribution and therapy (Butt et al., 2025). Still need to determine very well-defined dose response relationships for nanomedicines in PCOS, and also nonlinear kinetics which complicate predictions. There is a risk of poor efficacy from under-dosing which may also see over-dosing cause systemic toxicity or reproductive organ accumulation. In the case of computational tools like physiologically based pharmacokinetic (PBPK) modelling and simulation. That said until develop standard dosing strategies, dose optimization will be a key issue in the clinical translation of nanotherapy for PCOS. (*Holland-Letz & Kopp-Schneider, 2015*).

4.3 Reproducibility in Animal vs. Human Models

Another challenge in translating these findings is the reproducibility of preclinical results in other species. Animal models of PCOS, such as letrozole, dehydroepiandrosterone (DHEA), or testosterone-treated rodents, are commonly used to investigate the pathophysiology and assess new treatment options. However, these models only capture certain aspects of the heterogeneous nature of PCOS found in humans (Mahalmani et al. 2022a). While such rodent models show hyperandrogenism or cystic ovarian morphology, they tend to miss the other metabolic, reproductive, and psychological aspects that are seen in patients. Furthermore, the direct extrapolation of

the findings to humans is challenged due to the differences in the ovarian structure, immune system, metabolic rates, and other reproductive aspects. These differences cause the reproducibility challenges seen where promising clinical trial results in animal studies fail to translate to efficacy (Ryu et al., 2019). To that overcome this issue, the introduction of three-dimensional ovarian organoids, endometrial spheroids, and organ-on-a-chip models that use patient cells. These systems put forth a more physiological setting in which to study nanotherapy, but at present, their use in translational research is very much in the early stages. (*Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects*, n.d.).

4.4 Toxicity and Long-Term Safety Concerns

Even with the therapeutic potential nanomedicine holds, there is still a primary concern about its clinical use. Concerns about liver, spleen, kidneys, and ovary toxicity (due to the accumulation of nanomedicine in these organs) are still present. As the condition has underlying oxidative stress, silver and gold nanoparticles (which are inflammatory and also produce reactive oxidative species) would only aggravate this further (Yang & Merlin, 2023). Specific to this condition, the modulation of nanocarriers on hormonal control, oocyte maturation and folliculogenesis can be disruptive. Hypersensitivity and, as a result, cytokine storm syndromes are also related to the nanocarriers. Long-term negative consequences of these substances, particularly regarding fertility, are largely undefined, as are the outcomes of these on the child's health. To address these issues, rigorous safety evaluation is required, including chronic exposure studies, reproductive toxicity testing, and multi-generational animal studies. Regulatory agencies emphasize comprehensive safety profiling before approving nanomedicines intended for women of reproductive age, making toxicity one of the most stringent translational hurdles(*The Interaction between Nanoparticles and Immune System: Application in the Treatment of Inflammatory Diseases | Journal of Nanobiotechnology | Full Text*, n.d.).

4.5 Manufacturing Challenges: Scalability, Stability, and Cost

Translation of PCOS nanotherapy is also immensely affected by manufacturing challenges apart from biological and safety barriers. While there is precise control of the size, charge and encapsulation efficiency of nanoparticles synthesized at the laboratory scale, when scaled to industrial production, there will be variance and quality control issues. Consistency is vital for cross-clinical use and is an obtainable goal for the synthesis of individual batches; however, there is inconsistency in the synthesis of large batches. Another drawback is the stability of nanoparticles, as they may aggregate, leak the drug prematurely, or degrade (Balash et al., 2025). Also in play is the issue of cost, which is tied to the use of special raw materials and also to the requirement of very strict good manufacturing practice (GMP) facilities. High production costs may in turn affect access, which in turn is a particular issue in low-resource settings that also happen to have high PCOS prevalence. For regulatory approval which is a must standardized characterising techniques such as particle size analysis, zeta potential measurement, and drug release profiling to be used yet note that

their use is very much a hit and miss affair across research groups (Mehta et al., 2023). Also in the field of innovation are growth in the use of continuous manufacturing, green synthesis, and lyophilisation-based stabilisation which are put forth as solutions to these issues. But until we develop large-scale, stable, and cost-effective production systems which also take into account the economic issues of the settings in which they will be used, wide-scale clinical adoption of nanotherapy for PCOS is still some way off (Ahmad et al., 2024).

5. REGULATORY AND ETHICAL BARRIERS

Translation of nanotechnology-based therapies for PCOS is out that they are influenced by scientific and clinical issues, which also include regulatory and ethical issues. As PCOS does play in women of reproductive age, any therapeutic intervention requires very close watch to ensure they are safe and effective. Also there are no clear guidelines, safety evaluation criteria vary greatly and ethical issues and complex intellectual property problems, which in turn do not help progress from the lab to the patient. What is critical is to address these barriers which also include biological and technical issues, also it is the regulatory and ethical approval that determines the clinical success of PCOS nanotherapies(Shi et al., 2024).

5.1 Lack of Specific Regulatory Guidelines

Given the absence of specific worldwide governing bodies dealing with reproductive disorders, developing a condition-specific framework concerning reproductive disorders such as PCOS is nearly impossible. Most other available templates deal with the orthodox drug frameworks which fail to recognise the unique behaviour of nanocarriers, which include altered biodistribution, complex pharmacokinetics, and perhaps tissue sequestration. Considering the variability of PCOS, meeting DSM criteria in terms of regulation is complex since many of the therapeutics address the dual issues of metabolic and reproductive dysfunctions(Ali et al., 2023). Most often, the regulatory approval of nanomedicine in other domains, such as oncology and infectious diseases, serves as an indirect guide. However, such guides do not address issues of fertility and hormonal regulation which are of primary importance. Because a specific guide is not available, it tends to delay the translation of findings in the clinical sciences and negatively impact the interests of an industry. For this specific area to advance, it is crucial to develop guidelines concerning the safety and dosing, as well as the reproductive implications of the use of nanotherapy that is tailored to PCOS(Mangla et al., 2025).

5.2 Safety Assessment Protocols

International institutions like the Organisation for Economic Co-operation and Development (OECD), the United States Food and Drug Administration (FDA), and the European Medicines Agency (EMA) have put forth for large-scale nanomaterial safety evaluation. This includes have in terms of particle characterisation, toxicology testing, and biodistribution analysis. But when it comes to reproductive nanomedicine,

what is put forth falls short (*Recent Advances and FDA Approvals in Nanoformulations for Drug Delivery | Journal of Nanoparticle Research*, n.d.). For instance, it is the case that reproductive health issues like folliculogenesis, oocyte quality, or maternal-fetal safety are not looked at in standard toxicological assays. Also observe that the present OECD test guidelines report mainly on environmental and industrial nanomaterials and not so much on therapeutic uses. The FDA and EMA do put out detailed safety data requirements, but there is great variation in how nanocarrier-related issues are played out across regions. Also have the issue of a lack of harmonised reproductive health-specific safety protocols, which in turn creates uncertainty for researchers and manufacturers. To do better, regulators include reproductive health parameters in nanomedicine safety evaluations which in turn will ensure that they have attention to the particular health issues women with PCOS face(Miller et al., 2024).

5.3 Ethical Issues in Reproductive Nanomedicine

The ethical implications of nanotechnology and PCOS are also different from general drug development. A significant proportion of patients are women of childbearing age. Therapy risks must be evaluated not only for certain side effects but also for fertility, pregnancy, and child health. Informed consent becomes even more important, as patients must be informed of the potential risks and long-term exposures of the unknown. With limited healthcare resources gaps growing gaps in healthcare equity, there are also concerns with access. Cost of production will be a barrier in high-resource settings (*Nanoparticle-Based Interventions for Polycystic Ovary Syndrome: A Review of Mechanisms and Therapeutic Potential - ScienceDirect*, n.d.). Ethical issues present themselves in the use of what are perhaps the most advanced technologies, like gene editing nanoparticles, or 3D reproductive models, which may put into question the line between therapeutic breakthrough and reproductive manipulation. Also brought to the fore are issues of the role of bioethics in oversight, open communication with patients, and the engagement of many stakeholders in the development of PCOS nanotherapies must be done responsibly (*Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials*, n.d.).

5.4 Intellectual Property and Commercialization Hurdles

Besides having to deal with ethical and regulatory concerns, commercialization also takes on other challenges. Many nanotherapeutics are guarded by layers of patents on the composition of each nanoparticle, the processes of drug encapsulation or loading, and the targeting ligands, as well as the procedures of drug formulation (Das et.al). The tangling of such intellectual property (IP) can bring forth lawsuits that stifle the advancement of a product and make its development more financially burdensome (Mangla et al, 2025). The lack of commercial focus of PCOS is comparable to that of other conditions, such as oncology and cardiovascular diseases, and consequently, these challenges are discouraging for pharmaceutical companies. Aside from these challenges, bridging the gap that exists from the bench to the market also comes with

challenges of its own for small-scale formulations. The principles of good manufacturing practice (GMP) are extensive and also add to the cost and other logistical challenges. The commercialization challenges within public-private partnerships and other frameworks, such as technology transfer and open innovation, are initiated by smaller research groups and other academic innovators. Without supportive policies and streamlined intellectual property frameworks, even promising nanotherapies for PCOS risk being stalled in early development stages rather than reaching patients(Ghafari et al., 2025b).

6. CLINICAL TRANSLATION AND CURRENT TRIALS

6.1 Status of nanotherapy trials in reproductive health

The integration of nanotechnology into reproductive health, such as in conditions like PCOS, is in extremely early phases but is very promising. Preclinical studies have aimed to assess the delivery of nanoparticles to improve ovarian function, reduce oxidative stress, and improve the bioavailability of therapies such as metformin, letrozole, or natural antioxidants. However, in most nanomedicine trials in reproductive health, the ongoing and completed studies focus mainly on oncology and fertility augmentation, as well as targeted delivery of hormones, without much application to PCOS to date(Shandilya et al., 2020). A few studies are reporting on nanoparticle formulations for controlled hormone delivery, antioxidant therapy, and metabolic regulation, which in turn is a sign of the field's growth in terms of nanotherapy's role in female reproductive health issues. Although progress has been made, the number of in-progress clinical trials is still low compared to what is seen in cancer or heart disease fields, which in turn points out the need for more focused research. Also that in terms of nanocarrier design improvements, better biocompatibility, and patient-centred approaches, which are what are allowing for more reproductive health nanomedicine trials. The following point will be explored from the early results of these studies will play a key role in the development of what is to become large-scale and widespread use of nanotherapy in PCOS treatment (*Therapeutic Nanoparticles and Their Targeted Delivery Applications - PMC*, n.d.).

6.2 Challenges in patient recruitment & study design

Patient enrollment in clinical trials for PCOS nanotherapies is a challenging task, which is a result of the complex nature of the disorder. PCOS presents in very different ways in each person, with some having more metabolic issues, some reproductive and others endocrine. This in turn makes it hard to create trials that have the same inclusion criteria and outcome measures. Also, patients may be reluctant to take part in studies that include novel nanotech interventions out of worry for safety issues, long-term toxicity, and also what that may do to their fertility (Che et al., 2023). Study design also requires careful attention to dosing regimens, control groups, and ethical considerations surrounding reproductive health(*Overview of Clinical Study Designs - PMC*, n.d.). A small number of patients, in addition to high variation of follow-up

rates, present, which in turn complicate the are derived from the data. This results in underpowered studies, which in turn do not report fully on the therapeutic value of nanomedicine. To improve on this need for better patient education, multi-centre cooperation, and flexible trial designs that take into account the variable nature of PCOS while at the same time protecting patient safety and trust (Beca et al., 2021).

6.3 Biomarker development for patient stratification

The in success of nanotherapy in PCOS is tied to the identification of reliable biomarkers which in turn will put patients into groups that are most responsive to treatment. PCOS is a collection of many pathophysiological issues which include insulin resistance, hyperandrogenism, and chronic inflammation. Without the right biomarkers, it is hard to tell which patients will benefit from certain nanotherapeutic approaches. Genomic, proteomic and metabolomic advances have brought to light opportunities to identify molecular signatures which in turn will lead to better patient selection. For instance biomarkers related to oxidative stress or disturbed hormone signaling could play a role in which matching patients to targeted nanocarriers which are designed to correct those issues. Also in to play companion diagnostics may be integrated into clinical trials to report in real time on therapeutic response. Developing and confirming these biomarkers will not only maximise patient outcomes but also accelerate the clinical translation of nanotherapies in PCOS by enabling tailored treatment methods (*A Machine Learning Approach for Non-Invasive PCOS Diagnosis from Ultrasound and Clinical Features | Scientific Reports*, n.d.).

6.4 Translational gaps: bench-to-bedside

While preclinical studies show promise, the research gaps, specifically the translation of nanotherapy for the treatment of PCOS into the clinical domain, are concerning. The major predictive limitations of preclinical studies are due to the use of animal models, as these models cannot accurately reflect the complex and multifaceted nature of PCOS in humans. Moreover, regulatory bodies require extensive, long-term safety, pharmacokinetic, and toxicity studies which there are currently none for this type of research. These gaps in the research of PCOS nanotherapy require the collaboration of the research, clinical, and regulatory fields, as well as the implementation of well-designed and carefully planned clinical trials. For PCOS nanomedicine to reach the clinical domain, the research gaps will have to be filled, and the delay in bench-to-bedside strategies will have to be overcome (Mahalmani et al., 2022b).

7. FUTURE DIRECTIONS

7.1 Personalized nanomedicine approaches

Personalized medicine in conjunction with nanotechnology presents great opportunities for the future of PCOS management. PCOS is a complex which includes a variety of symptoms that present in different ways in each patient, such as variable degrees of insulin resistance, hyperandrogenism, inflammation, and fertility issues. Due to the

individuality of each patient's case, a single treatment may not be enough. What nanomedicine does is use the information from the patient's metabolism and molecular make-up to put the medication and nutraceuticals right at the ovaries, endometrium, and into the bloodstream (Cinti et al., 2024). Personalized nanosystems that include biomarkers, patient-specific metabolic profiles, or hormone patterns, for better treatment results. For instance that lipid-based nanosystems filled with metformin may be tailored for women with dominant metabolic phenotypes, also in the same vein, polymeric nanoparticles, which put forward anti-androgenic agents, may do best in hyperandrogenic settings. The coming together of nanotech with personal health care brings about the best results, minimal side effects and improved patient compliance, which in turn gives way to very much the personalized care for PCOS (*The Promise of Nanotechnology in Personalized Medicine - PMC*, n.d.).

7.2 CRISPR & nanocarrier integration

Integrating CRISPR-Cas gene-editing tools with nano-vehicle systems is a game-changer in innovations for managing PCOS. CRISPR can eliminate a wide array of genetic and epigenetic issues linked with PCOS, including modifiers of insulin signalling, androgen production, and inflammatory cascades. The main barrier is figuring out a functional and safe way to deliver CRISPR components(*CRISPR Technology Information | Thermo Fisher Scientific - IN*, n.d.). Lipid Nanoparticles and polymeric systems are advanced nanocarriers and can encapsulate, safeguard, and customise delivery of Cas9 proteins, guide RNAs, or base editors to target ovarian or endometrial tissues. This combo can allow the precise editing of mutations to diseases or the regulation of genes related to the pathophysiology of PCOS. Still, in the beginning of the preclinical step, the CRISPR-nanocarrier platforms may one day provide a means for the permanent adjustment of PCOS and genetically related disposition. This advancement will need thorough safe testing, ethical scrutiny, and regulatory trials to be used clinically (Pandey et al., 2025).



Figure 7.1 Schematic representation of CRISPR–Cas9 non-viral delivery systems. The CRISPR–Cas9 components ribonucleoprotein complex (RNP), messenger RNA (mRNA), and plasmid DNA are encapsulated or loaded into various non-viral nanocarriers such as lipid nanoparticles, polymeric nanoparticles, extracellular vesicles, gold nanoparticles, and mesoporous silica nanoparticles. These nanocarriers facilitate intercellular and intracellular delivery of the CRISPR–Cas9 machinery, enabling efficient genome editing with reduced immunogenicity and enhanced safety compared to viral vectors.

7.3 Smart/stimuli-responsive nanoparticles

The coming generations of nanotherapeutics for PCOS will see the development of smart or stimuli-responsive nanoparticles that break and release their payload in response to certain physiological triggers. These triggers may be pH change, oxidative stress levels, hormonal fluctuations, or enzymatic action within the ovarian tissue. For example, the development of nanoparticles which, upon detection of high reactive oxygen species, will release antioxidants, a key element in the pathophysiology of PCOS. Also, hormone-responsive carriers that will time the drug release to match up with the menstrual cycle, which in turn will improve the synchronisation of therapy with reproductive physiology (*Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers - PMC*, n.d.). These adaptive mechanisms enhance efficiency, decrease systemic toxicity, and lessen the likelihood of overtreatment. Responsive nanocarriers also show potential for use in combination therapy, where several drugs intended to treat the metabolic and reproductive aspects of the condition are released in a controlled, sequential manner. Such a therapy, versatile in responding to the patient's condition in real time, would be a game-changer in the way PCOS is treated (Sabir et al., 2025).

7.4 AI/ML in 3-D model analysis

AI is seeing more and more use in the analysis of complex data that is generated from 3D PCOS models. These techs scale multi-omics data, cellular imaging, and functional assays which in turn identify patterns that are not at all obvious from classic analysis. Which integrated AI into 3D culture systems are able to do therapeutic prediction, patient stratification and optimization of nanotherapy formulations. For example, AI algorithms may be used to model drug release kinetics in ovarian organoids or to put forth the results of nanocarrier distribution across metabolic pathways (*Frontiers | Application of Machine Learning and Artificial Intelligence in the Diagnosis and Classification of Polycystic Ovarian Syndrome: A Systematic Review*, n.d.). Machine learning also plays a role in the design of personalized nanomedicine by which can be predict patient subsets that will see the greatest benefit from certain therapies. Also AI AI-based platforms which put forward virtual models before physical trials, are to be seen on a large scale in drug discovery and repurposing. In the end, our picture is that AI and ML will be key players in the transition of lab research into the clinic, which, in terms will make PCOS nanotherapies more predictable and patient-centred (*A Machine*

Learning Approach for Non-Invasive PCOS Diagnosis from Ultrasound and Clinical Features | Scientific Reports, n.d.).

8. EMERGING 3-D TECHNOLOGIES FOR PCOS MANAGEMENT

8.1 Organ-on-a-chip for ovarian and metabolic crosstalk

Organized into chips which present an advanced *in vitro* platform to model the ovarian microenvironment and systemic metabolic interactions related to PCOS, there are known microfluidic systems that put together ovarian cells with those of the vasculature, liver or fat tissue elements which in turn allows researchers to study hormonal changes, insulin resistance and inflammatory responses in real time. Also for PCOS, these organ-on-a-chip models, which allow for very precise study of how nanotherapies play out in the reproductive and metabolic pathways, which in turn present a more physiological relevant option to use which is traditional cell culture or animal models. (*Female Reproductive System Organ-On-A-Chip Model Development Services - Creative Biolabs*, n.d.). They also support high-throughput drug screening, enabling rapid assessment of efficacy and toxicity under conditions closely resembling human physiology (Pal et al., 2023). The incorporation of patient-derived cells further strengthens the translational value, allowing individualized disease modeling Individualized disease modeling is made better with the addition of patient-derived cells. Organs-on-a-chip systems represent closing the gap between preclinical and clinical studies, and working testing and validating nanomedicine-based interventions for PCOS (Juguilon et al., 2025).

8.2 3-D bioprinting for fertility restoration

3-D bioprinting technology has become available and may be used to restore fertility for women with PCOS. To recreate structures of ovarian tissue that support the follicle, hormone production and development, growth factors and biomaterials mixed with stem cells bio-ink are used. This modeling approach is also therapeutic for the severe cases of PCOS with restoration of reproductive function (Serrano et al., 2023). Biopengineered ovarian tissues present themselves as test beds for which to put forward nanotherapies that improve folliculogenesis or reduce fibrosis in the ovary. Also by the inclusion of nanocarriers in these bioprinted tissues may obtain localised and sustained delivery of therapeutic agents. At present, this is still very much in the experimental phase, but the coming together of 3D bioprinting and nanotechnology has great promise for regenerative solutions in reproductive health. In the fullness of time, these systems may develop into, which are personalized fertility treatments for PCOS patients with impaired ovarian function (Parihar et al., 2024).

8.3 multi-omics integration in 3-D systems

The PCOS' complex nature requires a multi-dimensional analysis which in turn sees benefit from the use of multi-omics platforms within 3D settings, which provide greater insight into the mechanism. Genomics, transcriptomics, proteomics and

metabolomics, when put together in organoid or bioprinted models allow researchers to study the molecular basis of PCOS in great detail(*Polycystic Ovarian Syndrome: A Review of Multi-Omics Analyses | Reproductive Sciences*, n.d.). Also when used in conjunction with nanotherapy testing, these approaches present patient-specific responses, identify new therapeutic targets and in turn guide personalized treatment. The multi-omic approach with 3D culture's synergy will see that future PCOS interventions are not only founded in mechanism but also translate in a clinical setting which in total will drive the growth of personalized medicine strategies (Rashidi et al., 2024).

8.4 Role in drug repurposing and discovery

So there is no misunderstanding or different points of view, and PCOS has to say what the 3d technologies of 3 D technologies for drug repurposing and the drug discoveries and PCOS has the 3D technologies for drug repurposing of PCOS. Another set of 3D technologies is the bioprinted and organ-on-a-chip device that is needed to manage PCOS(Parihar et al., 2024). It takes the 3D technologies, such as the nanocarrier system decrease reliance on animal models and improve the replication of the disease models used. Using 3D models to systems to determine the drug. All this lets us pick organoids and allows us to manage PCOS. 3D systems give systems that determine the safe drug formulation, decrease the time cost and let us determine the reproductive drug in 3D systems. PCOS. 3D models in systems. 3D systems give us the chance to manage the cost time in drug determining the drug and to determine the drug. the increasing safe drug. 3D models in systems. PCOS. and 3D models in systems(Dave et al., 2025).

CONCLUSION

Nanotechnology has been put forth as a revolutionary field in the management of PCOS, which is the complex interaction of metabolic, endocrine, and reproductive issues through its novel drug delivery and therapeutic approaches. There is a noticeable personal nanomedicine, CRISPR-based interventions, and smart responsive nanoparticles growing in use, which in turn allows for tailoring of treatments to the individual patient, which in turn improves efficacy and at the same time reduces system-wide side effects. Also to the introduction of 3D tech, such as organ-on-a-chip platforms, bioprinted ovarian models and multi-omics integrated models which is in the process of changing study and treat PCOS by providing very relevant physiological systems that bridge see in preclinical settings to the clinic. Also, artificial intelligence and machine learning are playing a large role in this transition by looking at large data sets, predicting how patients will respond to therapy and in the process also helping to stratify patients. Despite seeing promise in these areas, what is present are translatable issues, especially in safety evaluation, regulatory approval, manufacturing scale-up up and ethical issues in reproductive medicine. As we move forward, the map for PCOS nanotherapy will require input from many disciplines, strong clinical trial designs, and patient-centred approaches to put forth safe, effective and accessible treatments. With consistent innovation and incorporation of the best technology, nanomedicine can play a role in taking PCOS treatment out of the generalised intervention past and into personal, precise and future-oriented therapy, which in turn will greatly improve women's health.

Acknowledgement: Authors would like to thank Editors, Deep Science Publishers and Department of Pharmacy, Jagannath University for providing this opportunity.

Author Contribution: All authors have equal contributions in completion of this book chapter.

Funding: No funding.

Conflict of Interest: There is no conflict of interest.

REFERENCES

A machine learning approach for non-invasive PCOS diagnosis from ultrasound and clinical features | Scientific Reports. (n.d.). Retrieved October 9, 2025, from https://www.nature.com/articles/s41598-025-10453-9

Abdallah, A. B. E., El-Ghannam, M. A., Hasan, A. A., Mohammad, L. G., Mesalam, N. M., & Alsayed, R. M. (2023). Selenium Nanoparticles Modulate Steroidogenesis-Related Genes and Improve Ovarian Functions via Regulating Androgen Receptors Expression in Polycystic Ovary Syndrome Rat Model. *Biological Trace Element Research*, *201*(12), 5721–5733. https://doi.org/10.1007/s12011-023-03616-0

Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9868606/

Pal, Rahul & Pandey, Prachi & Chawra, Himmat & Khan, Zuber. (2025). Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. Pharmaceutical Nanotechnology. 13. 10.2174/0122117385367493250224103839.

Ali, F., Neha, K., & Parveen, S. (2023). Current regulatory landscape of nanomaterials and nanomedicines: A global perspective. *Journal of Drug Delivery Science and Technology*, *80*, 104118. https://doi.org/10.1016/j.jddst.2022.104118

Altammar, K. A. (2023). A review on nanoparticles: Characteristics, synthesis, applications, and challenges. *Frontiers in Microbiology*, *14*, 1155622. https://doi.org/10.3389/fmicb.2023.1155622

Alwan, S. H., & Al-Saeed, M. H. (2023). Silver Nanoparticles Biofabricated from Cinnamomum zeylanicum Reduce IL-6, IL-18, and TNF-α in Female Rats with Polycystic Ovarian Syndrome. *International Journal of Fertility and Sterility*, *17*(1), 80–84. https://doi.org/10.22074/IJFS.2022.539396.1189

Available Treatments and Adjunctive Therapies for Polycystic Ovarian Syndrome (PCOS) Patients of Reproductive Age: A Scoping Review—PMC. (n.d.). Retrieved September 27, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11524647/

Bae, G., Berezhnoy, G., Koch, A., Cannet, C., Schäfer, H., Kommoss, S., Brucker, S., Beziere, N., & Trautwein, C. (2023). Stratification of ovarian cancer borderline from high-grade serous carcinoma patients by quantitative serum NMR spectroscopy of metabolites, lipoproteins, and inflammatory markers. *Frontiers in Molecular Biosciences*, *10*, 1158330. https://doi.org/10.3389/fmolb.2023.1158330

Balash, M., Boucetta, H., & He, W. (2025). Factors affecting drug delivery system translation: A focus on advanced technologies, biological barriers, and regulatory challenges. *Journal of Controlled Release*, *387*, 114167. https://doi.org/10.1016/j.jconrel.2025.114167

Balasubramanian, A., Veluswami, K., Rao, S., Aggarwal, S., & Mani, S. (2024). Exploring Clustered Regularly Interspaced Short Palindromic Repeats-CRISPR-Associated Protein 9 (CRISPR-Cas9) as a Therapeutic Modality for Cancer: A Scoping Review. *Cureus*. https://doi.org/10.7759/cureus.64324

Barber, T. M., & Franks, S. (2021). Obesity and polycystic ovary syndrome. *Clinical Endocrinology*, *95*(4), 531–541. https://doi.org/10.1111/cen.14421

Basu, S., Biswas, P., Anto, M., Singh, N., & Mukherjee, K. (2024). Nanomaterial-enabled drug transport systems: A comprehensive exploration of current developments and future avenues in therapeutic delivery. *3 Biotech*, *14*(12), 289. https://doi.org/10.1007/s13205-024-04135-y

Beca, J. M., Chan, K. K. W., Naimark, D. M. J., & Pechlivanoglou, P. (2021). Impact of limited sample size and follow-up on single event survival extrapolation for health technology assessment: A simulation study. *BMC Medical Research Methodology*, *21*, 282. https://doi.org/10.1186/s12874-021-01468-7

Butt, M. A., Tabassum, S., Hardy, R. S., & Kiyani, M. M. (2025). Mechanistic insight into nanomedicine for polycystic ovary syndrome. *Molecular Biology Reports*, *52*(1), 618. https://doi.org/10.1007/s11033-025-10709-7

Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. (n.d.). Retrieved October 9, 2025, from https://www.mdpi.com/1420-3049/28/13/5145

Cao, H., Duan, L., Zhang, Y., Cao, J., & Zhang, K. (2021). Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. *Signal Transduction and Targeted Therapy*, *6*(1), 426. https://doi.org/10.1038/s41392-021-00830-x

Che, Y., Yu, J., Li, Y.-S., Zhu, Y.-C., & Tao, T. (2023). Polycystic Ovary Syndrome: Challenges and Possible Solutions. *Journal of Clinical Medicine*, *12*(4), 1500. https://doi.org/10.3390/jcm12041500

Chen, W., & Pang, Y. (2021). Metabolic Syndrome and PCOS: Pathogenesis and the Role of Metabolites. *Metabolites*, *11*(12), 869. https://doi.org/10.3390/metabo11120869

Christ, J. P., & Cedars, M. I. (2023). Current Guidelines for Diagnosing PCOS. *Diagnostics*, *13*(6), 1113. https://doi.org/10.3390/diagnostics13061113

Cinti, C., Trivella, M. G., Joulie, M., Ayoub, H., & Frenzel, M. (2024). The Roadmap toward Personalized Medicine: Challenges and Opportunities. *Journal of Personalized Medicine*, *14*(6), 546. https://doi.org/10.3390/jpm14060546

CRISPR Technology Information | Thermo Fisher Scientific—IN. (n.d.). Retrieved October 9, 2025, from https://www.thermofisher.com/in/en/home/life-science/genome-editing/genome-editing-learning-center/crispr-cas9-technology-information.html?ef_id=745af40fabfc1f21c9c49ce815d23757:G:s&s_kwcid=AL!3652!10!76759856878772!!!76760083577185!!471266840!12281555700229 31&cid=bid_clb_gme_r01_co_cp0000_pjt0000_bid00000_0se_bng_nt_pur_con

Dave, R., Pandey, K., Patel, R., Gour, N., & Bhatia, D. (2025). Leveraging 3D cell culture and AI technologies for next-generation drug discovery. *Cell Biomaterials*, *1*(3), 100050. https://doi.org/10.1016/j.celbio.2025.100050

Dewani, D., Karwade, P., & Mahajan, K. S. (2023). The Invisible Struggle: The Psychosocial Aspects of Polycystic Ovary Syndrome. *Cureus*. https://doi.org/10.7759/cureus.51321

Dixit, P. V., & Mishra, D. K. (2025). Nanotechnology advances in treatment of reproductive diseases: From bench to bedside. *Journal of Reproductive Healthcare and Medicine*, *6*, 1. https://doi.org/10.25259/JRHM_28_2024

Endometrial Organoids and Their Role in Modeling Human Infertility—PubMed. (n.d.). Retrieved October 9, 2025, from https://pubmed.ncbi.nlm.nih.gov/40498005/

Erten, O., & Yılmaz, B. N. (2018). Three-Dimensional Imaging in Orthodontics. *Turkish Journal of Orthodontics*, *31*(3), 86–94. https://doi.org/10.5152/TurkJOrthod.2018.17041

Ezeh, U., Chen, Y. I., Pall, M., Buyalos, R. P., Chan, J. L., Pisarska, M. D., & Azziz, R. (2024). Alterations in nonesterified free fatty acid trafficking rather than hyperandrogenism contribute to metabolic health in obese women with polycystic ovary syndrome. *Fertility and Sterility*, *121*(6), 1040–1052. https://doi.org/10.1016/j.fertnstert.2024.01.030

Fatemi Abhari, S. M., Khanbabaei, R., Hayati Roodbari, N., Parivar, K., & Yaghmaei, P. (2020). Curcumin-loaded super-paramagnetic iron oxide nanoparticle affects on apoptotic factors expression and histological changes in a prepubertal mouse model of polycystic ovary syndrome-induced by dehydroepiandrosterone—A molecular and stereological study. *Life Sciences*, *249*(March), 117515. https://doi.org/10.1016/j.lfs.2020.117515

Female Reproductive System Organ-On-A-Chip Model Development Services—Creative Biolabs. (n.d.). Retrieved October 9, 2025, from https://microfluidics.creative-biolabs.com/female-reproductive-system-organ-on-a-chip-model.htm

Friederich, J., & Lazarova-Molnar, S. (2024). Reliability assessment of manufacturing systems: A comprehensive overview, challenges and opportunities. *Journal of Manufacturing Systems*, *72*, 38–58. https://doi.org/10.1016/j.jmsy.2023.11.001

Frontiers | Application of machine learning and artificial intelligence in the diagnosis and classification of polycystic ovarian syndrome: A systematic review. (n.d.). Retrieved October 9, 2025, from https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2023.1106625/full

Fukutomi, R., Ohishi, T., Koyama, Y., Pervin, M., Nakamura, Y., & Isemura, M. (2021). Beneficial Effects of Epigallocatechin-3-O-Gallate, Chlorogenic Acid, Resveratrol, and Curcumin on Neurodegenerative Diseases. *Molecules*, *26*(2), 415. https://doi.org/10.3390/molecules26020415

Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025a). The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment. *Endocrine and Metabolic Science*, *17*, 100228. https://doi.org/10.1016/j.endmts.2025.100228

Ghafari, A., Maftoohi, M., Samarin, M. E., Barani, S., Banimohammad, M., & Samie, R. (2025b). The last update on polycystic ovary syndrome(PCOS), diagnosis criteria, and novel treatment. *Endocrine and Metabolic Science*, *17*, 100228. https://doi.org/10.1016/j.endmts.2025.100228

Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025). Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape. *WIREs Nanomedicine and Nanobiotechnology*, *17*(2), e70010. https://doi.org/10.1002/wnan.70010

Gorgey, A. S., Ennasr, A. N., Farkas, G. J., & Gater, D. R. (2021). Anthropometric Prediction of Visceral Adiposity in Persons With Spinal Cord Injury. *Topics in Spinal Cord Injury Rehabilitation*, *27*(1), 23–35. https://doi.org/10.46292/sci20-00055

Grant, P. (2010). Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. *Phytotherapy Research*, *24*(2), 186–188. https://doi.org/10.1002/ptr.2900

Guo, W., Xu, Y., Tian, T., Yang, S., Li, R., Qiao, J., & Zheng, X. (2023). Outcomes of the Next In Vitro Fertilization Cycle in Women with Polycystic Ovary Syndrome after a Failed In Vitro Maturation Attempt. *Journal of Clinical Medicine*, *12*(17), 5761. https://doi.org/10.3390/jcm12175761

Gupta, U., Kosey, S., & Pal, R. (2025). Advancements in nanotechnology-based targeted drug delivery systems for glioblastoma chemotherapy: A comprehensive review. *Journal of Drug Delivery Science and Technology*, *111*, 107181. https://doi.org/10.1016/j.jddst.2025.107181

Hanssen, N. M. J., Kraakman, M. J., Flynn, M. C., Nagareddy, P. R., Schalkwijk, C. G., & Murphy, A. J. (2020). Postprandial Glucose Spikes, an Important Contributor to Cardiovascular Disease in Diabetes? *Frontiers in Cardiovascular Medicine*, *7*, 570553. https://doi.org/10.3389/fcvm.2020.570553

Heery, Aprn, Aocns, Cbcn, M., Farley, PharmD, Bcop, S., Sparkman, PharmD, R., Healy, Bs, PharmD, J., Eighmy, PharmD, W., Zahrah, Md, G., & Zelkowitz, Md, R. (2020). Precautions for Patients Taking Aromatase Inhibitors. *Journal of the Advanced Practitioner in Oncology*, *11*(2). https://doi.org/10.6004/jadpro.2020.11.2.6

Holland-Letz, T., & Kopp-Schneider, A. (2015). Optimal experimental designs for dose–response studies with continuous endpoints. *Archives of Toxicology*, *89*(11), 2059–2068. https://doi.org/10.1007/s00204-014-1335-2

Höller, M., Steindl, H., Abramov-Sommariva, D., Kleemann, J., Loleit, A., Abels, C., & Stute, P. (2024). Use of Vitex agnus-castus in patients with menstrual cycle disorders: A single-center retrospective longitudinal cohort study. *Archives of Gynecology and Obstetrics*, *309*(5), 2089–2098. https://doi.org/10.1007/s00404-023-07363-4

Human organoid systems in modeling reproductive tissue development, function, and disease | Human Reproduction | Oxford Academic. (n.d.). Retrieved October 9, 2025, from https://academic.oup.com/humrep/article/38/8/1449/7147082?login=false

Intharuksa, A., Kuljarusnont, S., Sasaki, Y., & Tungmunnithum, D. (2024). Flavonoids and Other Polyphenols: Bioactive Molecules from Traditional Medicine Recipes/Medicinal Plants and Their Potential for Phytopharmaceutical and Medical Application. *Molecules*, *29*(23), 5760. https://doi.org/10.3390/molecules29235760

Jamshidi, N., & Cohen, M. M. (2017). The Clinical Efficacy and Safety of Tulsi in Humans: A Systematic Review of the Literature. *Evidence-Based Complementary and Alternative Medicine*, *2017*(1), 9217567. https://doi.org/10.1155/2017/9217567

Józkowiak, M., Kobylarek, D., Bryja, A., Gogola-Mruk, J., Czajkowski, M., Skupin-Mrugalska, P., Kempisty, B., Spaczyński, R. Z., & Piotrowska-Kempisty, H. (2023). Steroidogenic activity of liposomal methylated resveratrol analog 3,4,5,4′-tetramethoxystilbene (DMU-212) in human luteinized granulosa cells in a primary three-dimensional in vitro model. *Endocrine*, *82*(3), 681–694. https://doi.org/10.1007/s12020-023-03458-9

Juguilon, C., Khosravi, R., Radisic, M., & Wu, J. C. (2025). In Vitro Modeling of Interorgan Crosstalk: Multi-Organ-on-a-Chip for Studying Cardiovascular-Kidney-Metabolic Syndrome. *Circulation Research*, *136*(11), 1476–1493. https://doi.org/10.1161/CIRCRESAHA.125.325497

Jyoti *, Sonia, Chennu M. M. Prasada Rao, T. R. and R. K. S. (2025). Unveiling the Anti-Diabetic Potential of Quercetin As a Natural Bioactive Compound—A Review. *International Journal of Pharmacognosy*, *12*(1), 1–23. https://doi.org/10.13040/IJPSR.0975-8232.IJP.12(1).1-12

Kaushal, A., Musafir, A., Sharma, G., Rani, S., Singh, R. K., Kumar, A., Bhadada, S. K., Barnwal, R. P., & Singh, G. (2025). Revolutionizing Diabetes Management Through Nanotechnology-Driven Smart Systems. *Pharmaceutics*, *17*(6), 777. https://doi.org/10.3390/pharmaceutics17060777

Kim, K.-W. (2021). Unravelling Polycystic Ovary Syndrome and Its Comorbidities. *Journal of Obesity & Metabolic Syndrome*, *30*(3), 209–221. https://doi.org/10.7570/jomes21043

Kouame, K., Peter, A. I., Akang, E. N., Moodley, R., Naidu, E. C., & Azu, O. O. (2019). Histological and biochemical effects of Cinnamomum cassia nanoparticles in kidneys of diabetic Sprague-Dawley rats. *Bosnian Journal of Basic Medical Sciences*, *19*(2), 138–145. https://doi.org/10.17305/bjbms.2019.3481

Kumar, A., Sundaram, K., Teng, Y., Mu, J., Sriwastva, M. K., Zhang, L., Hood, J. L., Yan, J., Zhang, X., Park, J. W., Merchant, M. L., & Zhang, H. G. (2022). Ginger nanoparticles mediated induction of Foxa2 prevents high-fat diet-induced insulin resistance. *Theranostics*, *12*(3), 1388–1403. https://doi.org/10.7150/thno.62514

Kumar, R. (2023). Nanotechnology in herbal medicine: Challenges and future perspectives. In *Nanotechnology in Herbal Medicine* (pp. 515–548). Elsevier. https://doi.org/10.1016/B978-0-323-99527-6.00008-2

Liang, J., Gao, Y., Feng, Z., Zhang, B., Na, Z., & Li, D. (2023). Reactive oxygen species and ovarian diseases: Antioxidant strategies. *Redox Biology*, *62*, 102659. https://doi.org/10.1016/j.redox.2023.102659

Lino, C., Barrias, S., Chaves, R., Adega, F., Martins-Lopes, P., & Fernandes, J. R. (2022). Biosensors as diagnostic tools in clinical applications. *Biochimica et Biophysica Acta (BBA) - Reviews on Cancer*, *1877*(3), 188726. https://doi.org/10.1016/j.bbcan.2022.188726

Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J. L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., & Ma, Y. (2024). Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs. *Drug Design, Development and Therapy*, *Volume 18*, 1469–1495. https://doi.org/10.2147/DDDT.S447496

Livadas, S., Anagnostis, P., Bosdou, J. K., Bantouna, D., & Paparodis, R. (2022). Polycystic ovary syndrome and type 2 diabetes mellitus: A state-of-the-art review. *World Journal of Diabetes*, *13*(1), 5–26. https://doi.org/10.4239/wjd.v13.i1.5

Luo, E. D., Jiang, H. M., Chen, W., Wang, Y., Tang, M., Guo, W. M., Diao, H. Y., Cai, N. Y., Yang, X., Bian, Y., & Xing, S. S. (2023). Advancements in lead therapeutic phytochemicals polycystic ovary syndrome: A review. *Frontiers in Pharmacology*, *13*(January), 1–21. https://doi.org/10.3389/fphar.2022.1065243

Luo, X., Jia, K., Xing, J., & Yi, J. (2024). The utilization of nanotechnology in the female reproductive system and related disorders. *Heliyon*, *10*(3), e25477. https://doi.org/10.1016/j.heliyon.2024.e25477

Maan, P., Gautam, R., Vasudevan, S., Menon, G. R., Arora, A., Nair, A., Jabbar, P. K., & Arora, T. (2025). Pharmacological and Non-Pharmacological Interventions for Polycystic Ovary Syndrome (PCOS) in Indian Women: A Systematic Review and Meta-Analysis. *Pharmaceuticals*, *18*(5), 680. https://doi.org/10.3390/ph18050680

Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022a). Translational research: Bridging the gap between preclinical and clinical research. *Indian Journal of Pharmacology*, *54*(6), 393–396. https://doi.org/10.4103/ijp.ijp_860_22

Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022b). Translational research: Bridging the gap between preclinical and clinical research. *Indian Journal of Pharmacology*, *54*(6), 393–396. https://doi.org/10.4103/ijp.ijp_860_22

Malik, S., Singh, J., Goyat, R., Saharan, Y., Chaudhry, V., Umar, A., Ibrahim, A. A., Akbar, S., Ameen, S., & Baskoutas, S. (2023). Nanomaterials-based biosensor and their applications: A review. *Heliyon*, *9*(9), e19929. https://doi.org/10.1016/j.heliyon.2023.e19929

Mangla, B., Kumar, P., Javed, S., Pathan, T., Ahsan, W., & Aggarwal, G. (2025). Regulating nanomedicines: Challenges, opportunities, and the path forward. *Nanomedicine (London, England)*, *20*(15), 1911–1927. https://doi.org/10.1080/17435889.2025.2533107

Mechanistic Review on the Role of Gut Microbiota in the Pathology of Cardiovascular Diseases. (2024). *Cardiovascular & Hematological Disorders-Drug Targets*, *24*(1), 13–39. https://doi.org/10.2174/011871529X310857240607103028

Mehta, M., Bui, T. A., Yang, X., Aksoy, Y., Goldys, E. M., & Deng, W. (2023). Lipid-Based Nanoparticles for Drug/Gene Delivery: An Overview of the Production Techniques and Difficulties Encountered in Their Industrial Development. *ACS Materials Au*, *3*(6), 600–619. https://doi.org/10.1021/acsmaterialsau.3c00032

Meissner, H. O., Mscisz, A., Reich-Bilinska, H., Mrozikiewicz, P., Bobkiewicz-Kozlowska, T., Kedzia, B., Lowicka, A., & Barchia, I. (2006). Hormone-Balancing Effect of Pre-Gelatinized Organic Maca (Lepidium peruvianum Chacon): (III) Clinical responses of early-postmenopausal women to Maca in double blind, randomized, Placebo-controlled, crossover configuration, outpatient study. *International Journal of Biomedical Science: IJBS*, *2*(4), 375–394.

Merza, W. M., Yaseen, A. K., & Mahmood, M. A. (2025). FSH, LH, lipid and adipokines in Polycystic Ovary Syndrome: Clinical biochemistry insights for diagnosis and management. *The Journal of Steroid Biochemistry and Molecular Biology*, *251*, 106773. https://doi.org/10.1016/j.jsbmb.2025.106773

Miller, L. B., Feuz, M. B., Meyer, R. G., & Meyer-Ficca, M. L. (2024). Reproductive toxicology: Keeping up with our changing world. *Frontiers in Toxicology*, *6*, 1456687. https://doi.org/10.3389/ftox.2024.1456687

Mohammed, S., Cockburn, B. N., & Sundaram, V. (2024). Exploring the Novel Alternative and Modern Treatment Options for Polycystic Ovary Syndrome-A Review. *Integrative Medicine Reports*, *3*(1), 33–42. https://doi.org/10.1089/imr.2023.0045

Moka, M. K., Sriram, D. K., & George, M. (2025). Recent Advances in Individualized Clinical Strategies for Polycystic Ovary Syndrome: Evidence From Clinical Trials and Emerging Pharmacotherapies. *Clinical Therapeutics*, *47*(2), 158–167. https://doi.org/10.1016/j.clinthera.2024.11.015

Montanino Oliva, M., Gambioli, R., Forte, G., Porcaro, G., Aragona, C., & Unfer, V. (2022). Unopposed estrogens: Current and future perspectives. *European Review for Medical and Pharmacological Sciences*, *26*(8), 2975–2989. https://doi.org/10.26355/eurrev_202204_28629

Mukherjee, S., Chopra, H., Goyal, R., Jin, S., Dong, Z., Das, T., & Bhattacharya, T. (2024). Therapeutic effect of targeted antioxidant natural products. *Discover Nano*, *19*(1), 144. https://doi.org/10.1186/s11671-024-04100-x

Muskan, Gupta, D., & Negi, N. P. (2022). 3D bioprinting: Printing the future and recent advances. *Bioprinting*, *27*, e00211. https://doi.org/10.1016/j.bprint.2022.e00211

Muthukumaran, D., & Shanmugam, R. (2024a). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. https://doi.org/10.1016/j.jddst.2024.106348

Muthukumaran, D., & Shanmugam, R. (2024b). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. https://doi.org/10.1016/j.jddst.2024.106348

Muthukumaran, D., & Shanmugam, R. (2024c). Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential. *Journal of Drug Delivery Science and Technology*, *102*, 106348. https://doi.org/10.1016/j.jddst.2024.106348

Nanoparticle-based interventions for polycystic ovary syndrome: A review of mechanisms and therapeutic potential—ScienceDirect. (n.d.). Retrieved October 9, 2025, from https://www.sciencedirect.com/science/article/abs/pii/S1773224724010177

Nanoparticles for Polycystic Ovary Syndrome (PCOS) Therapy: Exosomes and Synthetic Nanoparticles, Challenges and Opportunities—PubMed. (n.d.). Retrieved October 9, 2025, from https://pubmed.ncbi.nlm.nih.gov/40892199/

Next-Generation Drug Delivery for Neurotherapeutics: The Promise of Stimuli-Triggered Nanocarriers—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC12191273/

Oguz, S. H., & Yildiz, B. O. (2021). An Update on Contraception in Polycystic Ovary Syndrome. *Endocrinology and Metabolism*, *36*(2), 296–311. https://doi.org/10.3803/EnM.2021.958

Overcoming the barriers of two-dimensional cell culture systems with three-dimensional cell culture systems: Techniques, drug discovery, and biomedical applications—ScienceDirect. (n.d.). Retrieved October 9, 2025, from https://www.sciencedirect.com/science/article/abs/pii/B9780128239667000037

Overview of clinical study designs—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11009715/

Pal, R., Pandey, P., Nogai, L., Arushi, Anand, A., Suthar, P., SahdevKeskar, M., & Kumar, V. (2023). THE FUTURE PERSPECTIVES AND NOVEL APPROACH ON GASTRO RETENTIVE DRUG DELIVERY SYSTEM (GRDDS) WITH CURRRENT STATE. *Journal of Population Therapeutics and Clinical Pharmacology*, *30*(17), 594-613. https://doi.org/10.53555/jptcp.v30i17.2852

Pandey, V., Sharma, S., & Pokharel, Y. R. (2025). Exploring CRISPR-Cas: The transformative impact of gene editing in molecular biology. *Molecular Therapy Nucleic Acids*, *36*(4), 102717. https://doi.org/10.1016/j.omtn.2025.102717

Parashar, A. K., Hardenia, A., Dwivedi, S. K., Saraogi, G. K., & Hardenia, S. (2025). Next-Generation Nucleic Acid Delivery: A Review of Nanobiosystem Design and Applications. *Current Gene Therapy*, *25*. https://doi.org/10.2174/0115665232367377250519114910

Parihar, A., Parihar, D. S., Gaur, K., Arya, N., Choubey, V. K., & Khan, R. (2024). 3D bioprinting for drug development and screening: Recent trends towards personalized medicine. *Hybrid Advances*, *7*, 100320. https://doi.org/10.1016/j.hybadv.2024.100320

Park, C. H., Park, J. H., & Suh, Y. J. (2024). Perspective of 3D culture in medicine: Transforming disease research and therapeutic applications. *Frontiers in Bioengineering and Biotechnology*, *12*. https://doi.org/10.3389/fbioe.2024.1491669

Park, M., Sharma, A., Kang, C., Han, J., Malika Tripathi, K., & Lee, H. J. (2022). N-Doped Carbon Nanorods from Biomass as a Potential Antidiabetic Nanomedicine. *ACS Biomaterials Science and Engineering*, *8*(5), 2131–2141. https://doi.org/10.1021/acsbiomaterials.1c01598

Polycystic Ovarian Syndrome: A Review of Multi-omics Analyses | Reproductive Sciences. (n.d.). Retrieved October 9, 2025, from https://link.springer.com/article/10.1007/s43032-025-01789-8

Prakash, S. (2023). Nano-based drug delivery system for therapeutics: A comprehensive review. *Biomedical Physics & Engineering Express*, *9*(5), 052002. https://doi.org/10.1088/2057-1976/acedb2

Prathamesh R. Sune, Kajal S. Jumde, Pooja R. Hatwar, Ravindra L. Bakal, Samiksha D. More, & Atharv V. Korde. (2024). Nanoparticles: Classification, types and applications: A comprehensive review. *GSC Biological and Pharmaceutical Sciences*, *29*(3), 190–197. https://doi.org/10.30574/gscbps.2024.29.3.046

Principles of nanoparticle design for overcoming biological barriers to drug delivery | Nature Biotechnology. (n.d.). Retrieved October 9, 2025, from https://www.nature.com/articles/nbt.3330

Purwar, A., & Nagpure, S. (2022). Insulin Resistance in Polycystic Ovarian Syndrome. *Cureus*. https://doi.org/10.7759/cureus.30351

Rabah, H. M., Mohamed, D. A., Mariah, R. A., Abd El-Khalik, S. R., Khattab, H. A., AbuoHashish, N. A., Abdelsattar, A. M., Raslan, M. A., Farghal, E. E., & Eltokhy, A. K. (2023). Novel insights into the synergistic effects of selenium nanoparticles and metformin treatment of letrozole—Induced polycystic ovarian syndrome: Targeting PI3K/Akt signalling pathway, redox status and mitochondrial dysfunction in ovarian tissue. *Redox Report*, *28*(1). https://doi.org/10.1080/13510002.2022.2160569

Rafiya, K., Awasthi, S., Qureshi, S. A., Hasan, N., & Ahmad, F. J. (2025). Recent Advances in Nanocarrier-mediated Combination Drug Therapy for Tackling Solid-resistant Tumors. *Current Drug Delivery*. https://doi.org/10.2174/0115672018341670241124150932

Rai, A., Shukla, S., Gupta, R. K., & Mishra, A. (2025). ALS: A Silent Slayer of Motor Neurons. Traditional Chinese Herbal Medicine as an Effective Therapy. *Current Pharmaceutical Design*, *31*(17), 1328–1346. https://doi.org/10.2174/0113816128329141241205063352

Raja, M. A., Maldonado, M., Chen, J., Zhong, Y., & Gu, J. (2021). Development and evaluation of curcumin encapsulated self-assembled nanoparticles as potential remedial treatment for pcos in a female rat model. *International Journal of Nanomedicine*, *16*, 6231–6247. https://doi.org/10.2147/IJN.S302161

Rashid, R., Mir, S. A., Kareem, O., Ali, T., Ara, R., Malik, A., Amin, F., & Bader, G. N. (2022). Polycystic ovarian syndrome-current pharmacotherapy and clinical implications. *Taiwanese Journal of Obstetrics and Gynecology*, *61*(1), 40–50. https://doi.org/10.1016/j.tjog.2021.11.009

Rashidi, N., Davidson, M., Apostolopoulos, V., & Nurgali, K. (2024). Nanoparticles in cancer diagnosis and treatment: Progress, challenges, and opportunities. *Journal of Drug Delivery Science and Technology*, *95*, 105599. https://doi.org/10.1016/j.jddst.2024.105599

Recent advances and FDA approvals in nanoformulations for drug delivery | Journal of Nanoparticle Research. (n.d.). Retrieved October 9, 2025, from https://link.springer.com/article/10.1007/s11051-024-06199-6

Recent Advances in the Management of Polycystic Ovary Syndrome: A Review Article—PMC. (n.d.). Retrieved September 27, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9440853/

Recent Review on Biological Barriers and Host–Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC11360117/

Rodríguez-Yoldi, M. J. (2021). Anti-Inflammatory and Antioxidant Properties of Plant Extracts. *Antioxidants*, *10*(6), 921. https://doi.org/10.3390/antiox10060921

Ryu, Y., Kim, S. W., Kim, Y. Y., & Ku, S.-Y. (2019). Animal Models for Human Polycystic Ovary Syndrome (PCOS) Focused on the Use of Indirect Hormonal Perturbations: A Review of the Literature. *International Journal of Molecular Sciences*, *20*(11), 2720. https://doi.org/10.3390/ijms20112720

Sabbadin, C., Andrisani, A., Zermiani, M., Donà, G., Bordin, L., Ragazzi, E., Boscaro, M., Ambrosini, G., & Armanini, D. (2016). Spironolactone and intermenstrual bleeding in polycystic ovary syndrome with normal BMI. *Journal of Endocrinological Investigation*, *39*(9), 1015–1021. https://doi.org/10.1007/s40618-016-0466-0

Sabir, S., Thani, A. S. B., & Abbas, Q. (2025). Nanotechnology in cancer treatment: Revolutionizing strategies against drug resistance. *Frontiers in Bioengineering and Biotechnology*, *13*, 1548588. https://doi.org/10.3389/fbioe.2025.1548588

Sahu, T., Ratre, Y. K., Chauhan, S., Bhaskar, L. V. K. S., Nair, M. P., & Verma, H. K. (2021). Nanotechnology based drug delivery system: Current strategies and emerging therapeutic potential for medical science. *Journal of Drug Delivery Science and Technology*, *63*, 102487. https://doi.org/10.1016/j.jddst.2021.102487

Salm, S., Rutz, J., Van Den Akker, M., Blaheta, R. A., & Bachmeier, B. E. (2023). Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments. *Frontiers in Pharmacology*, *14*, 1234701. https://doi.org/10.3389/fphar.2023.1234701

Sarkar, K., Chatterjee, A., Bankura, B., Bank, S., Paul, N., Chatterjee, S., Das, A., Dutta, K., Chakraborty, S., De, S., Al-Masud, A. A., Khan, G. A., Chattopadhyay, D., & Das, M. (2024). Efficacy of pegylated Graphene oxide quantum dots as a nanoconjugate sustained release metformin delivery system in in vitro insulin resistance model. *PLoS ONE*, *19*(8 August), 1–15. https://doi.org/10.1371/journal.pone.0307166

Serrano, D. R., Kara, A., Yuste, I., Luciano, F. C., Ongoren, B., Anaya, B. J., Molina, G., Diez, L., Ramirez, B. I., Ramirez, I. O., Sánchez-Guirales, S. A., Fernández-García, R., Bautista, L., Ruiz, H. K., & Lalatsa, A. (2023). 3D Printing Technologies in Personalized Medicine, Nanomedicines, and Biopharmaceuticals. *Pharmaceutics*, *15*(2), 313. https://doi.org/10.3390/pharmaceutics15020313

Shandilya, R., Pathak, N., Lohiya, N. K., Sharma, R. S., & Mishra, P. K. (2020). Nanotechnology in reproductive medicine: Opportunities for clinical translation. *Clinical and Experimental Reproductive Medicine*, *47*(4), 245–262. https://doi.org/10.5653/cerm.2020.03650

Shang, C., Lin, H., Fang, X., Wang, Y., Jiang, Z., Qu, Y., Xiang, M., Shen, Z., Xin, L., Lu, Y., Gao, J., & Cui, X. (2021). Beneficial effects of cinnamon and its extracts in the management of cardiovascular diseases and diabetes. *Food & Function*, *12*(24), 12194–12220. https://doi.org/10.1039/D1FO01935J

Sheikh, I. M., Hassan, O. A., Adam, S. M., Ali, A. I., Ogedegbe, O. J., Tabowei, G., Barbarawi, A., Yussuf, F. M., & Nor, M. A. (2023). Association of Pioglitazone With Major Adverse Cardiovascular Events, All-Cause Mortality, and Heart Failure Hospitalizations: A Systematic Review. *Cureus*. https://doi.org/10.7759/cureus.46911

Shi, M., Li, X., Xing, L., Li, Z., Zhou, S., Wang, Z., Zou, X., She, Y., Zhao, R., & Qin, D. (2024). Polycystic Ovary Syndrome and the Potential for Nanomaterial-Based Drug Delivery in Therapy of This Disease. *Pharmaceutics*, *16*(12), 1556. https://doi.org/10.3390/pharmaceutics16121556

Singh, D. (2025). Nanotechnology-based Diagnostic Approaches for Early Detection and Monitoring of Polycystic Ovary Syndrome (PCOS). *Current Analytical Chemistry*, *21*(4), 263–275. https://doi.org/10.2174/0115734110311450240612051821

Singh, S., Arya, V., Mishra, R. K., Rajput, S. K., & Dhanasekaran, M. (2024). Nanotechnology in the diagnosis and management of polycystic ovary syndrome: A systematic scoping analysis to improve patient care. *Next Research*, *1*(1), 100004. https://doi.org/10.1016/j.nexres.2024.100004

Su, P., Chen, C., & Sun, Y. (2025). Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. *Journal of Ovarian Research*, *18*(1), 34. https://doi.org/10.1186/s13048-025-01621-6

Teja, P. K., Mithiya, J., Kate, A. S., Bairwa, K., & Chauthe, S. K. (2022). Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview. *Phytomedicine*, *96*, 153890. https://doi.org/10.1016/j.phymed.2021.153890

The interaction between nanoparticles and immune system: Application in the treatment of inflammatory diseases | Journal of Nanobiotechnology | Full Text. (n.d.). Retrieved October 9, 2025, from https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-022-01343-7

The Promise of Nanotechnology in Personalized Medicine—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC9142986/

Therapeutic Nanoparticles and Their Targeted Delivery Applications—PMC. (n.d.). Retrieved October 9, 2025, from https://pmc.ncbi.nlm.nih.gov/articles/PMC7248934/

Tumour-on-Chip Models for the Study of Ovarian Cancer: Current Challenges and Future Prospects. (n.d.). Retrieved October 9, 2025, from https://www.mdpi.com/2072-6694/17/19/3239

Unluhizarci, K., Karaca, Z., & Kelestimur, F. (2021). Role of insulin and insulin resistance in androgen excess disorders. *World Journal of Diabetes*, *12*(5), 616–629. https://doi.org/10.4239/wjd.v12.i5.616

Vasudevan, S., Gautam, R., Maan, P., Arora, A., Ganie, A., Jabbar, P. K., & Arora, T. (2025). A sustainable public health framework for PCOS management in low- and middle-income countries: A narrative review. *Frontiers in Reproductive Health*, *7*. https://doi.org/10.3389/frph.2025.1627670

Veerasamy, R. (2024). Development of Nanoparticles: Recent Developments and Future Prospects. In S. Bose, A. C. Shukla, M. R. Baig, & S. Banerjee (Eds.), *Concepts in Pharmaceutical Biotechnology and Drug Development* (pp. 67–89). Springer Nature Singapore. https://doi.org/10.1007/978-981-97-1148-2_5

Wang, H., & Yang, L. (2025). Ovarian Mechanobiology: Understanding the Interplay Between Mechanics and Follicular Development. *Cells*, *14*(5), 355. https://doi.org/10.3390/cells14050355

Wang, K., Li, Y., & Chen, Y. (2023). Androgen excess: A hallmark of polycystic ovary syndrome. *Frontiers in Endocrinology*, *14*, 1273542. https://doi.org/10.3389/fendo.2023.1273542

Yang, C., & Merlin, D. (2023). Challenges to Safe Nanomedicine Treatment. *Nanomaterials*, *13*(7), 1171. https://doi.org/10.3390/nano13071171

Yilmaz, S., Yilmaz Sezer, N., Gönenç, İ. M., İlhan, S. E., & Yilmaz, E. (2018). Safety of clomiphene citrate: A literature review. *Cytotechnology*, *70*(2), 489–495. https://doi.org/10.1007/s10616-017-0169-1

Yoon, J. H., Ahn, S.-Y., Jung, S.-H., Lee, J.-J., Choi, W., Park, J. Y., Hong, A. R., Kim, H. K., & Kang, H.-C. (2021). Prevalence and Risk Factors for Adrenal Insufficiency in Patients with Multiple Myeloma Receiving Long-Term Chemotherapy including Corticosteroids: A Retrospective Cohort Study. *BioMed Research International*, *2021*(1), 2330417. https://doi.org/10.1155/2021/2330417

Zhao, H., Wang, D., Xing, C., Lv, B., Wang, X., & He, B. (2023). Pioglitazone can improve liver sex hormone-binding globulin levels and lipid metabolism in polycystic ovary syndrome by regulating hepatocyte nuclear factor-4α. *The Journal of Steroid Biochemistry and Molecular Biology*, *229*, 106265. https://doi.org/10.1016/j.jsbmb.2023.106265

Zhao, S., Tang, Y., Wang, R., & Najafi, M. (2022). Mechanisms of cancer cell death induction by paclitaxel: An updated review. *Apoptosis*, *27*(9–10), 647–667. https://doi.org/10.1007/s10495-022-01750-z